New hope for Hard-to-Treat cancers: first human trial of TT125-802 begins
NCT ID NCT06403436
First seen Nov 01, 2025 · Last updated Jun 13, 2026 · Updated 32 times
Summary
This early-stage study tests a new drug called TT125-802 in about 50 adults with advanced solid tumors (like lung cancer) that no longer respond to standard therapies. The main goals are to check the drug's safety and find the right dose. Researchers will also watch for any tumor shrinkage or slowing of disease growth.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre Hospitalier Universitaire Vaudois
Lausanne, 1890, Switzerland
-
Ente Ospedaliero Cantonale
Bellinzona, 6500, Switzerland
-
NEXT Oncology Barcelona
Barcelona, 08023, Spain
-
NEXT Oncology Madrid
Madrid, 28223, Spain
-
NEXT Oncology Virginia
Fairfax, Virginia, 22031, United States
-
Sarah Cannon Research Institute Oncology Partners
Nashville, Tennessee, 37203, United States
-
Vall d'Hebron Institute of Oncology
Barcelona, 08035, Spain
Conditions
Explore the condition pages connected to this study.